Form 4: Acrivon Therapeutics Director Acquires RSUs

Derek DiRocco, a Director at Acrivon Therapeutics, Inc., acquired 9,366 restricted stock units (RSUs) on May 18, 2026, with full vesting scheduled for May 18, 2027.

Summary

• Director Derek DiRocco acquired 9,366 restricted stock units (RSUs) on May 18, 2026.
• These RSUs represent a contingent right to receive one share of Acrivon Therapeutics' Common Stock.
• The RSUs are scheduled to vest in full on May 18, 2027, provided the Reporting Person remains in continuous service.
• The acquisition was made under a Rule 10b5-1(c) plan.
• DiRocco holds these RSUs for the benefit of RA Capital Management, L.P., specifically RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund II, L.P.
• The Reporting Person disclaims beneficial ownership of these RSUs and the underlying common stock, as any stock received upon settlement will offset advisory fees owed to the Adviser.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While director equity grants can signal confidence, the disclaimer of beneficial ownership and the nature of the RSUs as fee offsets temper any strong positive sentiment.

Positives

• Director acquisition of equity indicates confidence in the company's future prospects.
• The acquisition was made under a Rule 10b5-1(c) plan, suggesting a pre-determined and structured transaction.
• The RSUs are performance-based, tied to continuous service, aligning management incentives with long-term company success.

Negatives

• The Reporting Person disclaims beneficial ownership, indicating the equity is held for advisory fee offsets rather than direct personal investment.
• The RSUs are subject to vesting, meaning the ultimate benefit is contingent on continued employment.

Risks

• The primary risk is the potential forfeiture of RSUs if the Reporting Person's continuous service is not maintained through the vesting date of May 18, 2027.
• The disclaimer of beneficial ownership suggests a complex financial arrangement that could have implications for fee structures and advisory relationships.

Future Outlook

The RSUs are set to vest on May 18, 2027, contingent upon the Reporting Person's continued service. The ultimate benefit of these RSUs is tied to the company's performance and the Reporting Person's tenure.

Management Comments

• The Reporting Person disclaims beneficial ownership of the RSUs and underlying common stock, as any stock received upon settlement will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser.

Industry Context

StockSavvy.ai notes that director equity grants, especially RSUs, are common in the biotechnology and pharmaceutical sectors as a means to attract and retain talent and align incentives with long-term value creation. The involvement of RA Capital Management, a known life sciences investor, suggests a strategic relationship.

Related Party Transactions

• The acquisition of RSUs by Director Derek DiRocco is structured such that any stock received upon settlement will offset advisory fees owed by RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund II, L.P. to RA Capital Management, L.P. This indicates a related party transaction involving advisory services and equity compensation.

Stakeholder Impact

• Shareholders: The transaction itself does not immediately dilute share count but represents future potential issuance upon vesting. The disclaimer of beneficial ownership may raise questions about the true economic interest of the director.
• Employees: The structure highlights a compensation mechanism that can be used by other key personnel, potentially influencing employee retention strategies.
• Creditors: No direct impact on creditors is evident from this filing.
• Suppliers: No direct impact on suppliers is evident from this filing.

Next Steps

• Monitoring the continuous service of Derek DiRocco through May 18, 2027, to confirm vesting of RSUs.
• Observing the ongoing relationship and fee arrangements between Acrivon Therapeutics, RA Capital Management, and its associated funds.

Key Dates

Keywords

Acrivon Therapeutics, ACRV, Form 4, SEC Filing, Director, Restricted Stock Units, RSUs, Beneficial Ownership, Vesting, RA Capital Management, Equity Award